Zobrazeno 71 - 80
of 933
pro vyhledávání: '"Kazuto Nishio"'
Autor:
Kazuto Nishio, Tetsuya Mitsudomi, Shuta Tomida, Yoshihiko Fujita, Marco A. De Velasco, Hidetoshi Hayashi, Eri Banno, Yu Nakamura, Kenichi Suda, Kazuko Sakai, Hiroshi Mizuuchi, Katsuaki Sato, Yosuke Togashi, Masato Terashima
Growth inhibitory effect of collagen via the activation of the p38 signal in A549-DDR2 S768R. (A) Cellular proliferation of transfectant A549 cell lines. Cellular growth was examined using an MTT assay with or without stimulation with collagen I (10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d99673dc781f60539bb55756ce627c3
https://doi.org/10.1158/1078-0432.22456988.v1
https://doi.org/10.1158/1078-0432.22456988.v1
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Masaaki Miyazawa, Kenji Hirotani, Michiko Yamato, Hiroyasu Kaneda, Yoshikazu Hasegawa, Keita Kudo, Takafumi Okabe, Yasutaka Chiba, Kazuko Sakai, Osamu Maenishi, Sigeki Kato, Masayuki Takeda, Hidetoshi Hayashi, Kaoru Tanaka, Takayuki Takahama, Naoki Takegawa, Ryoji Kato, Hitomi Sakai, Shiki Takamura, Koji Haratani, Kimio Yonesaka
Cox proportional hazard model for PFS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::505dd07e89ca0903d27a29cfc2bd0676
https://doi.org/10.1158/1078-0432.22464515.v1
https://doi.org/10.1158/1078-0432.22464515.v1
Autor:
Tomohide Tamura, Noriyuki Koyama, Kazuto Nishio, Fumiaki Koizumi, Taizo Hirata, Yutaka Fujiwara, Hiroshi Nokihara, Yasuhide Yamada, Noboru Yamamoto, Kazuhiko Yamada
Purpose: E7080, an oral multitargeted receptor tyrosine kinase inhibitor, has antiangiogenic and antitumor activity. This Phase I study investigated maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK), pharmacodynamics (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::804fd00a46698f08eca12c525c105d63
https://doi.org/10.1158/1078-0432.c.6519344
https://doi.org/10.1158/1078-0432.c.6519344
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Masaaki Miyazawa, Kenji Hirotani, Michiko Yamato, Hiroyasu Kaneda, Yoshikazu Hasegawa, Keita Kudo, Takafumi Okabe, Yasutaka Chiba, Kazuko Sakai, Osamu Maenishi, Sigeki Kato, Masayuki Takeda, Hidetoshi Hayashi, Kaoru Tanaka, Takayuki Takahama, Naoki Takegawa, Ryoji Kato, Hitomi Sakai, Shiki Takamura, Koji Haratani, Kimio Yonesaka
Effect of using a combination of targeting B7-H3 and PD-L1 on body weight in the murine tumor model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d23b233794e7c93aca35e20ccea76fe
https://doi.org/10.1158/1078-0432.22464524
https://doi.org/10.1158/1078-0432.22464524
Autor:
Kazuto Nishio, Tetsuya Mitsudomi, Shuta Tomida, Yoshihiko Fujita, Marco A. De Velasco, Hidetoshi Hayashi, Eri Banno, Yu Nakamura, Kenichi Suda, Kazuko Sakai, Hiroshi Mizuuchi, Katsuaki Sato, Yosuke Togashi, Masato Terashima
Purpose: This study investigated whether mutations of receptor tyrosine kinase (RTK) genes detected using next-generation sequencing (NGS) are suitable therapeutic targets.Experimental design: Fifty surgically resected non–small cell lung cancer (N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::000e23faaad4f776d1d81008c3d57c61
https://doi.org/10.1158/1078-0432.c.6523472.v1
https://doi.org/10.1158/1078-0432.c.6523472.v1
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Takashi Kagari, Kenji Hirotani, Yuuri Hashimoto, Masanori Funabashi, Ryoto Yoshimoto, Maki Kobayashi, Hiroaki Okida, Eri Otsuka, Hiroki Goto, Asuka Tsuya, Yasutaka Chiba, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Hisato Kawakami, Koji Haratani, Osamu Maenishi, Junko Tanizaki, Kimio Yonesaka
Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::193a3c11e4e3e804b1cd4a8031602911
https://doi.org/10.1158/1078-0432.22487915.v1
https://doi.org/10.1158/1078-0432.22487915.v1
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Erina Hatashita, Haruka Yamaguchi, Kiyoko Kuwata, Ken Takezawa, Hiroyasu Kaneda, Hidetoshi Hayashi, Kaoru Tanaka, Kazuko Sakai, Takafumi Okabe, Isamu Okamoto, Junko Tanizaki
PDF file, 65K.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14f05eed2f1c81a2e6b94271f968b916
https://doi.org/10.1158/1078-0432.22446441
https://doi.org/10.1158/1078-0432.22446441
Autor:
Kazuto Nishio, Masatoshi Kudo, Nagahiro Saijo, Kazuko Matsumoto, Yoshihiko Fujita, Hideharu Kimura, Keiichi Aomatsu, Daisuke Tamura, Hiroyasu Kaneda, Kanae Kudo, Kazuko Sakai, Kazuyuki Furuta, Tokuzo Arao, Tomoyuki Nagai
Supplementary Figures 1-5 from Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72ac10c120b3fe794e966f736c11be4e
https://doi.org/10.1158/1535-7163.22483866.v1
https://doi.org/10.1158/1535-7163.22483866.v1
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Takashi Kagari, Kenji Hirotani, Yuuri Hashimoto, Masanori Funabashi, Ryoto Yoshimoto, Maki Kobayashi, Hiroaki Okida, Eri Otsuka, Hiroki Goto, Asuka Tsuya, Yasutaka Chiba, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Hisato Kawakami, Koji Haratani, Osamu Maenishi, Junko Tanizaki, Kimio Yonesaka
Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318557b3f697f81f5990207a8834d461
https://doi.org/10.1158/1078-0432.22487939.v1
https://doi.org/10.1158/1078-0432.22487939.v1
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Kazuko Sakai, Hidetoshi Hayashi, Hisato Kawakami, Junko Tanizaki, Koji Haratani, Hitomi Sakai, Ryoji Kato, Toshiyuki Takehara, Takeshi Teramura, Kimio Yonesaka, Shinichiro Suzuki
Purpose:Treatment with KRASG12C inhibitors such as sotorasib can produce substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC). These patients require alternative treatment after acquiring resistance to the inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515508c588c2e1caeb4109c863e2de8b
https://doi.org/10.1158/1078-0432.c.6530453.v1
https://doi.org/10.1158/1078-0432.c.6530453.v1